AKARI THERAPEUTICS, PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.21 USD | +2.54% |
|
+4.72% | -61.22% |
Financials (USD)
| Sales 2022 | - | Sales 2023 | - | Capitalization | 17.64M |
|---|---|---|---|---|---|
| Net income 2022 | -17M | Net income 2023 | -10M | EV / Sales 2022 | - |
| Net cash position 2022 | 13.25M | Net cash position 2023 | 3.84M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-1.65
x | P/E ratio 2023 |
-1.53
x | Employees | 11 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 28.78% |
More Fundamentals
* Assessed data
More news
Latest transcript on Akari Therapeutics, Plc
More recommendations
More press releases
| 1 day | +2.54% | ||
| 1 week | +4.72% | ||
| Current month | -35.12% | ||
| 1 month | -36.31% | ||
| 3 months | -54.51% | ||
| 6 months | -64.72% | ||
| Current year | -61.22% |
1 week
1.08
1.24
1 month
1.081.90
Current year
1.083.30
1 year
1.085.50
3 years
1.0854.80
5 years
1.0884.20
10 years
1.08522.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jacques Suzanne
CEO | Chief Executive Officer | 53 | 22-03-27 |
| Founder | 79 | 15-08-31 | |
Wendy DiCicco
DFI | Director of Finance/CFO | 56 | 23-07-18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Donald Williams
BRD | Director/Board Member | 65 | 16-05-31 |
| Founder | 79 | 15-08-31 | |
| Director/Board Member | 61 | 23-07-04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 1.18 | +1.18% | 13,919 |
| 24-04-19 | 1.166 | -3.62% | 3,740 |
| 24-04-18 | 1.21 | +7.92% | 8,776 |
| 24-04-17 | 1.121 | -2.97% | 7,933 |
| 24-04-16 | 1.156 | -3.71% | 14,524 |
Delayed Quote Nasdaq, April 23, 2024 at 04:30 pm EDT
More quotes
Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). It is conducting a clinical trial of subcutaneous nomacopan for the treatment of HSCT-TMA in pediatrics. The United States Food and Drug Administration (FDA) has granted Rare Pediatric Disease, Orphan Drug, and Fast Track designations to nomacopan for the treatment of pediatric HSCT-TMA. It is also investigating long-acting PASylated-nomacopan (PAS-nomacopan) for treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) in preclinical studies.
Calendar
| 1st Jan change | Capi. | |
|---|---|---|
| -61.22% | 9.35M | |
| -0.49% | 103B | |
| +3.31% | 96.73B | |
| +1.66% | 21.31B | |
| -16.16% | 21.21B | |
| -6.82% | 18.79B | |
| -41.41% | 16.37B | |
| -22.87% | 13.68B | |
| +6.32% | 13.44B | |
| +21.46% | 10.98B |
- Stock Market
- Equities
- AKTX Stock
